Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
First-line Chemotherapy
100%
Maintenance Therapy
100%
Esophagogastric Cancer
100%
Survival Benefit
66%
Trastuzumab
66%
HER2-positive
66%
Advanced Esophageal Cancer
66%
Maintenance Strategy
33%
Drug Combination
33%
Non-small Cell Lung Cancer (NSCLC)
33%
Stable Disease
33%
Median Overall Survival
33%
Overall Survival
33%
Patient's Will
33%
Maintenance Treatment
33%
Cancer Center
33%
Progression-free Survival
33%
Interim Analysis
33%
Objective Response Rate
33%
Patient Selection
33%
Metastatic Disease
33%
Doublet
33%
Efficacy Endpoint
33%
Phase II Clinical Trial
33%
Triplet
33%
Human Epidermal Growth Factor Receptor 2 (HER2)
33%
Capecitabine
33%
Novel Treatments
33%
Platinum-based Chemotherapy
33%
Previously Treated
33%
Fluoropyrimidine-based Chemotherapy
33%
Randomized Phase II Trial
33%
HER2+
33%
Ineffective Treatment
33%
6-cycles
33%
Locally Advanced Unresectable
33%
Progression-free
33%
RECIST 1.1
33%
Resectable Disease
33%
Adaptive Trial Design
33%
Anti-PD-1
33%
Second-line Chemotherapy
33%
PD-L1 Inhibitor
33%
Clinical Trial Information
33%
Medicine and Dentistry
Arm
100%
Maintenance Therapy
100%
Treatment Planning
100%
Abdominal Cancer
100%
First-Line Chemotherapy
33%
Clinical Trial
22%
Overall Survival
22%
Progression Free Survival
22%
Trastuzumab
22%
Malignant Neoplasm
11%
Metastatic Carcinoma
11%
Combination Drug
11%
Biological Marker
11%
Interim Analysis
11%
Immunotherapy
11%
Capecitabine
11%
Fluoropyrimidine
11%
Non-Small Cell Lung Cancer
11%
Second-Line Chemotherapy
11%
Diseases
11%